Company profile: NovaBay Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of biopharmaceutical eye care products, including Avenova Antimicrobial Lid and Lash Solution, Novawipes by Avenova, Avenova Lubricant Eye Drops, and Avenova Moist Heating Eye Compress, plus proprietary hypochlorous acid wound care solutions: NeutroPhase for cleansing and irrigating wounds (China) and PhaseOne for cleansing post-surgical wounds (US, professional use).
Products and services
- Avenova Antimicrobial Lid and Lash Solution: Antimicrobial solution engineered to remove microorganisms and debris from the skin around the eye, including the eyelid, supporting eyelid and lash cleansing
- PhaseOne: Proprietary hypochlorous acid formulation used for cleansing post-surgical wounds, distributed in the United States for professional use, supporting postoperative wound hygiene
- NeutroPhase: Proprietary hypochlorous acid formulated for cleansing and irrigating wounds, distributed in China, for wound cleansing and irrigation applications.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NovaBay Pharmaceuticals
Scynexis
HQ: United States
Website
- Description: Provider of drug discovery, development and manufacturing projects focused on antifungal therapeutics, including ibrexafungerp, a novel oral/IV glucan synthase inhibitor for serious and resistant fungal infections; SCY-247, a second-generation broad-spectrum triterpenoid; VVC and RVVC treatments; and the MARIO study evaluating oral step-down after IV echinocandin for invasive candidiasis and candidemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scynexis company profile →
Alphyn Biologics
HQ: United States
Website
- Description: Provider of proprietary drug therapies for skin diseases, including Zabalafin hydrogel (AB-101a), a steroid-free topical for atopic dermatitis targeting immune and bacterial components; the Zabalafin (AB-101) multi-bioactive platform; and AB-101b in development for Epidermolysis Bullosa to address inflammation, itch, pain, and skin infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alphyn Biologics company profile →
GenePOC
HQ: Canada
Website
- Description: Provider of accurate, cost-effective molecular solutions to detect pathogen genes, featuring a simple, stand-alone system for prevention and early detection of infectious diseases based on unique microfluidic technology; a privately owned member of Debiopharm Group.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenePOC company profile →
Sherlock Biosciences
HQ: United States
Website
- Description: Provider of engineering biology-based molecular diagnostics leveraging CRISPR and synthetic biology, including SHERLOCK for DNA/RNA detection and INSPECTR for instrument-free ambient tests, plus an FDA-authorized CRISPR SARS-CoV-2 kit. Offers global health partnerships to develop and distribute affordable infectious disease diagnostics and an internship & co-op program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sherlock Biosciences company profile →
Cubist
HQ: United States
Website
- Description: Provider of biopharmaceutical products focused on the research, development, and commercialization of therapies addressing unmet medical needs in the acute care environment; markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cubist company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NovaBay Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NovaBay Pharmaceuticals
2.2 - Growth funds investing in similar companies to NovaBay Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NovaBay Pharmaceuticals
4.2 - Public trading comparable groups for NovaBay Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →